about
Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infantsEffectiveness of Granulocyte Colony-Stimulating Factor in Hospitalized Infants with Neutropenia.Changes in the incidence of candidiasis in neonatal intensive care units.Variability in vancomycin use in newborn intensive care units determined from data in an electronic medical record.Reported medication use in the neonatal intensive care unit: data from a large national data set.Empirical therapy for neonatal candidemia in very low birth weight infants.Diuretic exposure in premature infants from 1997 to 2011Safety of milrinone use in neonatal intensive care unitsRifampin use and safety in hospitalized infants.Safety of octreotide in hospitalized infants.Safety of High-dose Acyclovir in Infants With Suspected and Confirmed Neonatal Herpes Simplex Virus Infections.The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system--tools for "meaningful use" in continuous quality improvement.Early and late onset sepsis in late preterm infants.Varying patterns of home oxygen use in infants at 23-43 weeks' gestation discharged from United States neonatal intensive care units.Association of in utero magnesium exposure and spontaneous intestinal perforations in extremely low birth weight infantsMedication use in the neonatal intensive care unitFrequency of anomalies and hospital outcomes in infants with gastroschisis and omphalocele.Late-onset bloodstream infections in hospitalized term infants.Aminoglycoside-mediated relaxation of the ductus arteriosus in sepsis-associated PDA.Comparative effectiveness of digoxin and propranolol for supraventricular tachycardia in infants.Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants.Repeat lumbar punctures in infants with meningitis in the neonatal intensive care unit.Clinical outcomes in very low birth weight infants with major congenital heart defects.No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants.Treatment of supraventricular tachycardia in infants: Analysis of a large multicenter database.Coagulase-negative staphylococcal infections in the neonatal intensive care unitVery late onset infections in the neonatal intensive care unit.Necrotizing enterocolitis in infants with ductal-dependent congenital heart disease.Nosocomial infection in the NICU: a medical complication or unavoidable problem?Prevention and treatment of nosocomial sepsis in the NICU.Characteristics of patients who die of necrotizing enterocolitis.Insulin, Hyperglycemia, and Severe Retinopathy of Prematurity in Extremely Low-Birth-Weight Infants.Management Practice and Mortality for Infants with Congenital Diaphragmatic Hernia.Sedatives and Analgesics Given to Infants in Neonatal Intensive Care Units at the End of LifeAntifungal therapy and outcomes in infants with invasive Candida infections.Adverse Events After Routine Immunization of Extremely Low-Birth-Weight Infants.Use and Safety of Erythromycin and Metoclopramide in Hospitalized Infants.Cefepime and Ceftazidime Safety in Hospitalized Infants.Safety of histamine-2 receptor blockers in hospitalized VLBW infants.Association between positive urine cultures and necrotizing enterocolitis in a large cohort of hospitalized infants.
P50
Q24601509-57E64079-9389-42F0-9357-B74FB1E068EBQ30275884-89AF8575-8938-416C-A118-CA9E3AACB3A0Q30408409-76A127AF-3D9A-4C31-B75E-645581B6261DQ31157309-3DAC7727-138F-47D1-BF46-83F4EBF61B16Q33245443-7181EEA8-20D1-4F09-8146-6C39FC6F1CDFQ33349749-AB46118E-8E9D-47CE-8634-548839490FB4Q33415111-AA288AAC-8AA7-448B-A0D6-564FDFFBD3A5Q33419080-3F26CF39-3B1D-44F0-B02B-1FF1446C8D8EQ33419821-34DEAD17-A448-45B6-8E3E-65DC9CB05643Q33422773-09ED6DE7-BA44-41EA-A5E8-64F084F266BAQ33437643-1F13768F-9E12-4539-B488-4D6DB0AE5C92Q33549058-BE973B21-F603-4406-A713-BC9D9177C121Q33559246-A62352EF-AB07-4047-BB59-EEF725B308D8Q33635057-22FFB789-F7C5-461D-A041-05EFA73881BAQ33732421-8860498E-88F6-4C09-8495-5B03336EB3E9Q33769958-90793E48-9E85-4AE8-9F8D-17BB27C8D00DQ33993188-A786EA0F-B2A9-4C2A-BF35-6860E0F844D6Q34161144-CD44C6A3-AEA0-4092-98DA-261EE0C626BDQ34296748-85672031-C25C-48CA-A586-40C9222DB7C2Q34458246-00C45723-24EA-4A77-9D02-57EEDFB68AA4Q34785435-F565C0C7-5ADD-4DFE-B2C2-B6A9EDD69A00Q35011962-BDC9C15F-6E9D-4D8A-94CD-9423B929543BQ35032542-591CDC6D-11B4-4ED0-AF1A-AF35798D2ACAQ35170480-B4978032-2DAC-4831-91F7-4BA380FA5904Q35613224-799F7844-A032-42AC-94F3-5AC781C94FC7Q35614039-1432ADF5-9C22-49FB-A7FF-E251FA68AD4DQ35643346-0149543F-BF6C-4925-A244-56C7E46B1E77Q35667589-EB519B67-4DD1-4279-80C0-53CE1D89DAFAQ35759567-75557928-CE87-4450-8F5B-F5918418EDB7Q35765537-1EA749C5-3087-453A-8A5C-2E1E18B246C5Q35788579-EAE1C7BD-C828-42C1-BEEE-139B96417AAEQ35814629-B2643AD6-6FF7-4B4B-A598-BEB6EED8A98BQ35893744-7320A67A-5BA3-44C0-9441-FABDDF20E3E9Q35893978-BEB0DC01-2E03-41BD-8A58-AB8DD12ED956Q35897495-0392967E-2C04-45AF-908F-8B04F07BB629Q35911931-ED8CF661-619C-419F-9AB0-CB33F40FB62EQ36005912-5B8F9515-E159-4DCB-892C-30375EEACBA8Q36069519-7D13F930-88D7-4CC6-8941-DA7C420BCBB2Q36070675-03A39721-A5F0-42F0-9ECC-731AC854AA3DQ36074443-DC9CE1D6-4003-45FD-9C86-4FBA2DA980CA
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Reese H Clark
@ast
Reese H Clark
@en
Reese H Clark
@es
Reese H Clark
@nl
Reese H Clark
@sl
type
label
Reese H Clark
@ast
Reese H Clark
@en
Reese H Clark
@es
Reese H Clark
@nl
Reese H Clark
@sl
prefLabel
Reese H Clark
@ast
Reese H Clark
@en
Reese H Clark
@es
Reese H Clark
@nl
Reese H Clark
@sl
P106
P108
P21
P31
P3835
reese-clark
P496
0000-0002-7363-4640
P569
2000-01-01T00:00:00Z